Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI

Inclusion Criteria: * Informed consent signed and dated by study patient and investigator/authorised physician * Minimum age of 18 years * Ability to understand the nature and requirements of the study Study-specific inclusion criteria: * Patients with indication for lipoprotein apheresis confirmed by a local apheresis expert commission according to the German guidelines \[1\] and with routine lipoprotein apheresis treatments for at least 3 months. Patients with weekly treatments have not missed more than 3 treatment sessions within the 3 months prior inclusion to the study. Patients with biweekly treatment sessions have not missed more than 1 treatment session within the 3 months prior inclusion to the study * Patients with regular weekly or biweekly lipoprotein apheresis treatments with either MONET or DIAMED lipoprotein apheresis systems for at least 4 weeks (weekly treatments) or 8 weeks (biweekly treatments) with the same system * With adequate venous access * With systolic blood pressure \> 100 mmHg * With stable hematocrit \>35 % * With stable anticoagulation Exclusion Criteria: * Any condition which could interfere with the patient's ability to comply with the study * Pregnancy or lactation period (pregnancy test will be conducted with female patients aged 55 years) * Participation in an interventional clinical study during the preceding 30 days or in the same study Study-specific exclusion criteria: * Occurrence or clinical relevant deterioration of acute myocardial infarction, unstable angina pectoris, severe hemo-dynamic relevant arrhythmia within 3 months prior inclusion to the study * Bypass surgery, vascular diseases, active infection (this means chronic infectious diseases (e.g. chronic hepatitis) and acute infections with a core body temperature ≥ 38.0 °C) or unstable circulation (see exclusion criteria no. 7) within the last 3 months * Uncontrolled high or low blood pressure defined as systolic blood pressure \>180 mmHg/\<100 mmHg and/or diastolic blood pressure \>115 mmHg (after three times measuring) * Changes in lipid lowering medication within the last 2 weeks * Intake of Angiotensin Converting Enzyme (ACE) inhibitor medication within a time interval of five times the terminal half-life of the ACE inhibitor before study start and during the study * History of allergic reactions to anticoagulation